Literature DB >> 19602723

The effect of progesterone on myometrial contractility, potassium channels, and tocolytic efficacy.

Laurie Anderson1, William Martin, Claire Higgins, Scott M Nelson, Jane E Norman.   

Abstract

OBJECTIVES: Recent clinical trials have demonstrated a beneficial effect of supplementation with progesterone to prevent preterm labor. We aimed to determine the effects of progesterone treatment in vitro and in vivo and 17alpha-hydroxyprogesterone caproate (17OHPC) in vitro on myometrial contractions.
METHODS: Myometrial strips were taken from women undergoing cesarean delivery at term. We also obtained myometrial biopsies from women participating in a clinical trial of progesterone to prevent preterm labor in twins (STOPPIT). After establishment of spontaneous contractions, strips were exposed to progesterone or 17OHPC. Separate strips were exposed to oxytocin and tocolytics alone and in combination with progesterone. Potassium channel blockers were added in conjunction with progesterone. STOPPIT samples were used to compare the effects of in vivo progesterone and placebo. We measured amplitude, frequency and activity integral of contractions.
RESULTS: Maximum inhibition of contraction amplitude was 93 +/- 2% and 67 +/- 14% for progesterone at 30 microM and vehicle (70% ethanol), respectively, P < 0.05. 17OHPC did not exert an inhibitory effect. Water soluble progesterone exerted a maximal inhibitory effect on amplitude of contractions of 82 +/- 10% at 100 microM, P < 0.05. The inhibitory effect of progesterone was unaffected by potassium channel blockers. There was no difference between in vivo placebo and progesterone-treated groups in either amplitude or frequency of contractions, nor was there any difference in the response to oxytocin or the tocolytic drugs.
CONCLUSIONS: Progesterone exerts rapid inhibition of the amplitude of myometrial contractions in vitro but 17OHPC does not. The action of progesterone does not appear to operate via potassium channels nor does it enhance the activity of certain tocolytic drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602723     DOI: 10.1177/1933719109340926

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  17 in total

Review 1.  17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth.

Authors:  Emma D Deeks
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

2.  Progesterone Metabolites Produced by Cytochrome P450 3A Modulate Uterine Contractility in a Murine Model.

Authors:  Avinash S Patil; Geeta K Swamy; Amy P Murtha; R Phillips Heine; Xiaomei Zheng; Chad A Grotegut
Journal:  Reprod Sci       Date:  2015-06-02       Impact factor: 3.060

Review 3.  Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations.

Authors:  Maisa Feghali; Raman Venkataramanan; Steve Caritis
Journal:  Semin Perinatol       Date:  2014-09-23       Impact factor: 3.300

4.  Effects of progesterone treatment on expression of genes involved in uterine quiescence.

Authors:  Melvyn S Soloff; Yow-Jiun Jeng; Michael G Izban; Mala Sinha; Bruce A Luxon; Susan J Stamnes; Sarah K England
Journal:  Reprod Sci       Date:  2011-08       Impact factor: 3.060

5.  Progesterone blocks multiple routes of ion flux.

Authors:  Brooke G Kelley; Paul G Mermelstein
Journal:  Mol Cell Neurosci       Date:  2011-07-19       Impact factor: 4.314

6.  Vaginal progesterone, but not 17α-hydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.

Authors:  Amy-Eunice Furcron; Roberto Romero; Olesya Plazyo; Ronald Unkel; Yi Xu; Sonia S Hassan; Piya Chaemsaithong; Arushi Mahajan; Nardhy Gomez-Lopez
Journal:  Am J Obstet Gynecol       Date:  2015-08-08       Impact factor: 8.661

Review 7.  Progesterone is not the same as 17α-hydroxyprogesterone caproate: implications for obstetrical practice.

Authors:  Roberto Romero; Frank Z Stanczyk
Journal:  Am J Obstet Gynecol       Date:  2013-04-30       Impact factor: 8.661

8.  Expression of the small conductance Ca²⁺-activated potassium channel subtype 3 (SK3) in rat uterus after stimulation with 17β-estradiol.

Authors:  Mette Rahbek; Sasan Nazemi; Lars Odum; Saurabh Gupta; Steen Seier Poulsen; Anders Hay-Schmidt; Dan Arne Klaerke
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

9.  The interaction between vaginal microbiota, cervical length, and vaginal progesterone treatment for preterm birth risk.

Authors:  Lindsay M Kindinger; Phillip R Bennett; Yun S Lee; Julian R Marchesi; Ann Smith; Stefano Cacciatore; Elaine Holmes; Jeremy K Nicholson; T G Teoh; David A MacIntyre
Journal:  Microbiome       Date:  2017-01-19       Impact factor: 14.650

Review 10.  Androgens in pregnancy: roles in parturition.

Authors:  Sofia Makieva; Philippa T K Saunders; Jane E Norman
Journal:  Hum Reprod Update       Date:  2014-03-18       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.